CN102335353A - Application of traditional Chinese medicine Tangcao tablets in preparation of medicines used for increasing leukocyte - Google Patents
Application of traditional Chinese medicine Tangcao tablets in preparation of medicines used for increasing leukocyte Download PDFInfo
- Publication number
- CN102335353A CN102335353A CN2010102293969A CN201010229396A CN102335353A CN 102335353 A CN102335353 A CN 102335353A CN 2010102293969 A CN2010102293969 A CN 2010102293969A CN 201010229396 A CN201010229396 A CN 201010229396A CN 102335353 A CN102335353 A CN 102335353A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- tablets
- herba
- blade
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides an application of traditional Chinese medicine Tangcao tablets in the preparation of medicines used for increasing leukocyte. The traditional Chinese medicine Tangcao tablets are prepared from raw materials of: common heron bill herb, mongolian milkvetch root, black nightshade herb, honeysuckle flower, common bombax flower, common terminalia fruit, spreading hedyotis herb, pomegranate bark, glutinousae rice root, water caltrop, mongolian snakegourd rind, Chinese thorowax root, Chinese mosla herb, suberect spatholobus stem, safflower, ginkgo leaf, purslane, figwortflower picrorhiza rhizome, and scorpion. The taditional Chinese medicine Tangcao tablets are used in a curative effect test of mice leucopenia caused by chemotherapeutics, and results show that: the tablets provides a substantial effect for increasing leukocyte, and the tablets assists in increasing a comprehensive curative effect. Therefore, indications of the traditional Chinese medicine Tangcao tablets are increased, and the application scope is enlarged. The traditional Chinese medicine Tangcao tablets can be used in preparing medicines used for increasing leukocyte. The tablets have a relatively large clinical application value, and bring substantial social benefit and economic benefit.
Description
Technical field
The present invention relates to Chinese medicine, be specifically related to the new indication of Chinese medicine Tang blade, relate in particular to the application of Chinese medicine Tang blade in preparation leukocyte increasing medicine.
Background technology
Chinese medicine Tang blade is the Chinese medicine preparation that is obtained through selected, check, science compatibility, modernized processing and preparing by 20 pleasant impression selected Chinese medicinal materials.The constituent of Chinese medicine Tang blade is many, comprises Herba Erodii, Flos Lonicerae, Pericarpium Trichosanthis, Radix Bupleuri, Herba Moslae, Pericarpium Granati, the Radix Astragali, Radix Glycyrrhizae, Flos Bombacis Malabarici, Caulis Spatholobi, Flos Carthami, Radix Oryzae Glutinosae, Fructus Chebulae, Herba Hedyotidis Diffusae, Pedicellus et Pericarpium Trapae, Folium Ginkgo, Herba Portulacae, Rhizoma Picrorhizae, Herba Solani Nigri, Scorpio etc.The compound structure multiformity that each becomes branch to comprise; Make the target spot of its generation effect more, modern pharmacological research shows that it has effect, the liver protecting of clear and definite inhibition HIV virus replication, human body immunity improving function, the immunocyte of repairing damage, oxidation and removing free radicals, delays the process of AIDS, defence patient's effects such as opportunistic infection.
Chinese medicine Tang blade prescription has embodied the integral body of Chinese medicine and has nursed one's health, consolidated eliminating evil theory; In clinical practice, constantly sum up perfect again; Can be used for the male viral infection person of HIV at present, remedied the deficiency of therapeuticcocktail of anti-retrovirals, can be used as HIV sufferers's auxiliary treatment means simultaneously again.The characteristics of Chinese medicine Tang blade are determined curative effect, all can take symptomless infection person and each phase AIDS patient.Take the anti-virus ability that this medicine can strengthen self for a long time, improve the cd4 cell number, improve whole quality of life of patient.Be the model that natural drug is used to treat AIDS.The birth of Chinese medicine Tang blade is that resisting on the medical history of AIDS also is a milestone on the history of Chinese materia medica.The inventor studies the quality of Chinese medicine Tang blade, and the method for quality control of Chinese medicine Tang blade is provided, and has applied for that the Chinese invention patent application number is 200910048798.6-" quality standard and the detection method of Chinese medicine Tang blade ".
At present, with the treatment of some anti-AIDS drugs or along with disease progression, because the bone marrow depression meeting causes leucocytes reduction, like the zidovudine in efficient ART (HAART) scheme etc.Because leukocytic minimizing causes body's immunity to descend, and is prone to cause opportunistic infection.And that AIDSinfected patient itself is exactly a cellular immune function is impaired, therefore, in treatment, can bring the side effect of leukocytic minimizing.In addition; Cause the hemopoietic bone marrow depression in the therapeutic process of antitumor drug more easily; And its effect of medicine that frequent clinically at present some that use have leukocyte increasing is still limited, therefore seeks to have the bone marrow protection, alleviates chemotherapeutics toxicity; Reduce the toxic and side effects that chemotherapy produced, the life quality that improves the patient has very important significance.The inventor finds that Tang's blade has the effect of leukocyte increasing in constantly studying.
Summary of the invention
Technical problem to be solved by this invention is to overcome above-mentioned weak point, the new indication of research design Chinese medicine Tang blade, expanding application scope.
The invention provides the application of Chinese medicine Tang blade in preparation leukocyte increasing medicine.
Chinese medicine according to the invention Tang blade is the legal listing medicine of China national SFDA approval, and its raw material of Chinese medicine constituent and process route are the legal content of national SFDA approval.Be following weight proportion:
Herba Erodii 120-150, Radix Astragali 120-150, Herba Solani Nigri 120-200, Flos Lonicerae 120-200, Flos Bombacis Malabarici 60-100, Fructus Chebulae 40-60, Herba Hedyotidis Diffusae 80-150, Pericarpium Granati 40-60, Radix Oryzae Glutinosae 150-200, Pedicellus et Pericarpium Trapae 80-150, Pericarpium Trichosanthis 40-60, Radix Bupleuri 60-100, Herba Moslae 40-60, Radix Glycyrrhizae 60-80, Caulis Spatholobi 120-150, Flos Carthami 40-60, Folium Ginkgo 40-60, Herba Portulacae 60-120, Rhizoma Picrorhizae 40-60, Scorpio 28-40.
Preferably, the raw material of Chinese medicine constituent of Chinese medicine according to the invention Tang blade is following weight proportion:
Herba Erodii 120-150, Radix Astragali 120-150, Herba Solani Nigri 120-200, Flos Lonicerae 120-200, Flos Bombacis Malabarici 60-100, Fructus Chebulae 40-60, Herba Hedyotidis Diffusae 80-150, Pericarpium Granati 40-60, Radix Oryzae Glutinosae 150-200, Pedicellus et Pericarpium Trapae 80-150.
Preferred, the raw material of Chinese medicine constituent of Chinese medicine according to the invention Tang blade is following weight proportion:
Herba Erodii 180, the Radix Astragali 180, Herba Solani Nigri 180, Flos Lonicerae 180, Flos Bombacis Malabarici 120, Fructus Chebulae 90, Herba Hedyotidis Diffusae 180, Pericarpium Granati 90, Radix Oryzae Glutinosae 300, Pedicellus et Pericarpium Trapae 180.
The inventor observes Chinese medicine Tang blade causes leucocytes reduction to medicine leukogenic effect through setting up the leucocytes reduction animal model of stable Chinese medicine screening research.The inventor gropes on the basis with reference to various kinds of document repeatedly, and it is the new method of derivant that mitomycin has been set up in design, not only is fit to observe leukocytic influence, also can observe hematoblastic influence.Use mitomycin and cause normal mouse leucocytes reduction model; The animal that makes of ability long period is in the leucocytes reduction level; Tumor-bearing mice is accepted the mitomycin treatment and is added the blade with Chinese medicine Tang simultaneously; Get the variation that peripheral blood is measured cell number such as leukocyte at different time, observe Tang's blade in drug-induced leucocytes reduction role.
The present invention is the leukogenic effect of Tang's blade after deliberation; Find Chinese medicine Tang blade in, can accelerate the chemotherapeutics effect when low dose is used in advance after leukocytic rise; Promptly has function of increasing leukocyte; Than at least 10 days in advance recovery time of leukocyte of model control group, neutrophilic granulocyte, lymphocyte also almost return to normal level synchronously, are indicating the body's immunological function recovery.In the research process; Use present clinical generally acknowledged leukocyte increasing comparison effective chemical medicine recombinant human granulocyte colony stimulating factor and made positive control drug; 4 angel's leukocyte return to normal level after Tang's blade group onset, and all there are good effect the intensity of rising and persistent period.
On the other hand, when being used for leukopenia that chemotherapeutics causes, whether can influence the antitumor action of chemotherapeutics preventative for observing Chinese medicine Tang blade, the present invention has carried out Chinese medicine Tang blade the influence of mouse entity tumor and ascites tumor has been studied.The result shows that the application Chinese medicine blade low dosage 0.5g/kg of Tang, middle dosage 1.0g/kg body weight treatment group return to normal level in advance than model group.And the antitumor action of chaff rimocidin not; Even the enhancing antitumor action arranged; Inhibitory rate to 43.5%; Greatly surpassed singlely, also surpassed effective standard of chemicals 40%, can preventatively be used for the treatment of the leukopenia that chemotherapeutics causes with mitomycin group tumour inhibiting rate 11.4%.Result of study explanation Chinese medicine Tang blade does not influence the antitumor action of chemotherapeutics when liter is white.Dosage, low dose group can promote leukocytic rising in the model in the Chinese medicine Tang blade, and similar to neutrophilic granulocyte and lymphocytic facilitation and leukocyte, Chinese medicine Tang blade low dose group leukogenic effect is more obvious; Middle dosage Chinese medicine Tang blade also has the effect of certain leukocyte increasing.Chinese medicine Tang blade can increase animal bone marrow colony forming cell number, is the embodiment of its function of increasing leukocyte.Chinese medicine Tang blade accepts in the chemotherapeutics mitomycin therapeutic process effect of leukocyte increasing is arranged at tumor animal.Chinese medicine Tang blade and antitumor drug share the antitumor action that can improve antineoplastic chemotherapy medicine.Chinese medicine Tang blade can be alleviated the inhibitory action of antitumor drug to bone marrow.
In addition; The present invention's research is observed Chinese medicine Tang blade in treatment AIDS; Also having the protection hemopoietic function of bone marrow, accelerate the recovery of body's immunity and alleviate the myelosuppressive untoward reaction of conventional anti-AIDS drug (like zidovudine etc.), also is important innovations point of the present invention.
The low dosage leukogenic effect of Tang of the present invention blade is better, rises white clinical use amount and is not higher than 16 at every turn, three times on the one.
Tang of the present invention blade rise white optimal clinical using dosage at every turn smaller or equal to 8, three times on the one.
Tang of the present invention blade rises white optimal clinical using dosage and is≤13.7 grams for be equivalent to take the medical material amount at every turn.
It is to be equivalent to take the medical material amount every day to be≤41.1 grams that Tang of the present invention blade rises white best taking dose.
Chinese medicine Tang blade has the effect of anti-AIDS, also has the effect of leukocyte increasing simultaneously, the untoward reaction that can resist the other drug therapeutic scheme; Improve the comprehensive therapeutic effect of treatment, increase the indication of Chinese medicine Tang blade, the expanding application scope; Can be used for preparing the medicine of function of increasing leukocyte; Fully show the treatment advantage of Chinese medicine, bigger clinical value is arranged, have obvious social and economic benefit.
The specific embodiment
Embodiment 1
The blade leukocyte increasing pharmacodynamic study test of Chinese medicine Tang
The present invention uses mitomycin and causes normal mouse leucocytes reduction model, makes leukocyte ease down to below 35% of matched group, the modelling success.Find in the experiment that drug dose is excessive, bone marrow depression is dark excessively, and leukopenia is too many; Animal is dead easily, also is unfavorable for pharmaceutically-active performance, and the present invention adopts mouse peritoneal injection mitomycin 3mg/kg once; Inject mitomycin 2mg/kg scheme once after five days again, animal tolerates easily, and it is long to hold time after the leukopenia; Medicine has sufficient action time; And therapeutic regimen is more near the application method of clinical practice, show real hemopoietic and suppress, rather than the exhaustion of peripheral leukocytes.Mitomycin is the broad-spectrum antitumor drug, and the inhibitory action of hemopoietic simultaneously is also more intense, longer duration, and the drug effect that such model shows is reliable.
One. purpose: observe the curative effect of Chinese medicine Tang blade to the caused leukopenia of chemotherapeutics.
Two. material and method:
1. laboratory animal: Kunming kind healthy mice, the cleaning level, male, body weight 31 ± 2 grams.
2. medicine and reagent: mitomycin for inj: Haizheng Medicine Stock Co., Ltd., Zhejiang Prov, lot number: 090302
Recombinant human granulocyte colony stimulating factor: Quangang Medicine Co., Ltd., Shandong Prov., lot number: 200812901
Chinese medicine Tang blade: Shanghai Baisuixing Pharmaceutical Co., Ltd produces, lot number: 081203, and every 0.4g, containing the crude drug amount is 1.708g.
(Herba Erodii 180g, Radix Astragali 180g, Herba Solani Nigri 180g, Flos Lonicerae 180g, Flos Bombacis Malabarici 120g, Fructus Chebulae 90g, Herba Hedyotidis Diffusae 180g, Pericarpium Granati 90g, Radix Oryzae Glutinosae 300g, Pedicellus et Pericarpium Trapae 180g.Process 1000)
3. animal model: according to document (Akahori H; Shibuya K; Ozai M; Et al.Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.Stem Cells.1996,14 (6): 678-689; Shimomura K, Manda T, Mukumoto S; Et al.Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973; In mice.Cancer Res.1988,48 (5): 1166-1172), adopt following method with the preliminary experiment result; Mouse peritoneal injection mitomycin 3mg/kg once injects mitomycin 2mg/kg once after five days again.
4. the leukocyte increasing experiment is divided into groups and dosage: animal is divided into 6 groups at random according to body weight, 10 every group.Be divided into dose groups, model+Chinese medicine Tang blade high dose group, positive drug control group in normal control group, model group, model+Chinese medicine Tang blade low dose group, the model+Chinese medicine Tang blade.Chinese medicine Tang blade adopts the oral administration mode of forcing.Chinese medicine Tang blade is settled to after with physiological saline solution volume required, and animal is irritated the long-pending 0.1ml/10g body weight of pressing of body of stomach.The Chinese medicine Tang basic, normal, high dosage of blade is followed successively by 0.5,1.0, the 2.0g/kg body weight; Chinese medicine Tang blade medication pneumoretroperitoneum injection in 5 days mitomycin; Chinese medicine Tang blade continuous irrigation clothes 21 days; Normal control group, model group are irritated clothes equivalent normal saline, and positive drug control group is subcutaneous injection recombinant human granulocyte colony stimulating factor 50 μ g/kg in model success back, inject continuously 4 days.
Tumor animal experiment divide into groups with dosage (Xu Shuyun edits. pharmacological experimental methodology. second edition. Beijing: the People's Health Publisher, 1994.1243-1249): animal is divided into 5 groups at random according to body weight, 6 every group.Be divided into normal control group, tumor animal group, tumor animal+Chinese medicine Tang blade (1.0g/kg body weight) group, tumor animal+Chinese medicine Tang blade (1.0g/kg body weight)+mitomycin (5.0mg/kg body weight) group, tumor animal+mitomycin (5.0mg/kg body weight) group.Prophylactic applications Chinese medicine Tang blade 5 days is given mouse inoculation Mus S180 sarcoma and ascites tumor (10 respectively
7/ only, 0.2ml), treatment with chemotherapy Mitomycin C 5.0mg/kg treatment simultaneously in second day is once.Inoculation Mus S180 sarcoma group (formation solid tumor) Chinese medicine Tang blade successive administration 11 days, ascites tumor group Chinese medicine Tang blade successive administration 18 days.
Three. observation index:
1. numeration of leukocyte: get mouse tail vein blood 50 μ l by conventional method, add and contain in the 150 μ l normal saline of EDTA-2K, mixing is counted PBL (WBC) number, platelet (PLT) number, erythrocyte (RBC) number etc. respectively with cellanalyzer.Different time counting cells after administration respectively, model group animal peripheral white blood cell stops when returning to normal level.
2. the femur nucleated cell is counted: when experiment finishes, put to death mice with mercy killing, get a side femur, go out bone marrow nucleated cell by routine, with hematimeter counting nucleated cell number.The bone marrow colony forming cell is cultivated: when experiment finishes, put to death mice with mercy killing, get a side femur bone marrow cell, do methylcellulose with 6 orifice plates and cultivate, every sample is established 3 holes, the main grain-mononuclear cell colony number (CFU-GM) of observing.
3. the weight of animals: respectively before administration with administration after different time weighing the weight of animals.
4. tumor animal life-span of observing tumour inhibiting rate (solid tumor) and animal respectively prolongs (ascites tumor) situation, and measures variation such as PBC number.
Four. statistical disposition: experimental data is with mean scholar standard deviation (X ± s) expression; Use the SPSS10.0 analysis software experimental data is carried out statistical analysis; Adopt the one factor analysis of variance method of a plurality of sample average comparisons to carry out statistical analysis, get P＜0.05 and be the significance test level.
Five. experimental result
1. the checking of experimental model
From table 1, can find out; Injected for the first time behind the mitomycin 4 days, the model group leukocyte count reduces not obvious, injects for the second time behind the mitomycin 6 days; Promptly injected for the first time behind the mitomycin 10 days; The model group leukocyte count significantly is lower than 35% of normal control group, compares with the normal control group to have significant difference, and the modelling success is described.The leukocyte of the animal pattern of setting up, platelet count can continue 30 days low-level, and erythrocyte continues 7 days.
2. the variation of peripheral white blood cell
The variation (* 10 of table 1 peripheral white blood cell
9/ L)
Annotate: * and matched group ratio, P＜0.05;
▲Compare P＜0.05 with model group
Inject for the first time 18 days (model built up the 8th day) behind the mitomycin, each is organized leukocyte count and is not seen rebound significantly; In the time of the 24th day, in the Chinese medicine Tang blade, low dose group and positive controls leukocyte count be apparently higher than model control group (P＜0.05), reaches C group, lasted till the 33rd day always.In the time of the 40th day, the leukocyte count of dose groups, positive controls has begun to descend in the Chinese medicine Tang blade, and Chinese medicine Tang blade low dose group still maintains higher level.Can find out that from table 1 it is also not obvious that Chinese medicine Tang blade early prevention is used the reduction leukocyte effect that resists mitomycin, but the effect that promotes that leukocyte raises is arranged late period.3. the variation of neutrophilic granulocyte and lymphocyte number
The variation tendency of neutrophilic granulocyte and lymphocyte number and the variation tendency of peripheral white blood cell are unanimous on the whole, and just Chinese medicine Tang blade low dose group has shown rising neutrophilic granulocyte and lymphocyte effect.
The variation (* 10 of table 2 peripheral blood neutrophil number
9/ L)
Annotate: * and matched group ratio, P＜0.05;
▲Compare P＜0.05 with model group
The variation (* 10 of table 3 PBLC number
9/ L)
Annotate: * and matched group ratio, P＜0.05;
▲Compare P＜0.05 with model group
4. the variation of other blood cell counts
The variation (* 10 of table 4 peripheral red blood cells number
12/ L)
Annotate: * and matched group ratio, P＜0.05;
▲Compare P＜0.05 with model group
In injection preceding 24 days behind the mitomycin, each medication group RBC number raises and is not obvious; But after the 33rd day, Chinese medicine Tang blade low dose group RBC number is higher than model group, lasts till that always experiment finishes, and results suggest Chinese medicine Tang blade also has the erythrocytic effect of certain rising.5. bone marrow cell and medullary cell are cultivated the variation of back colony number
Can find out from table 5; Each organizes bone marrow nucleated cell, and to count difference little; Wherein Chinese medicine Tang blade low dose group has shown downward trend, possibly be that this group various types of cells number has reached normal level, and the regulating action of body self has begun to suppress due to the hemopoietic function of bone marrow.
The variation of table 5 bone marrow nucleated cell number (/ root femur)
Colony number (/ 10 after table 6 bone marrow cells in mice is cultivated
5)
Annotate: * and matched group ratio, P＜0.05,
▲Compare P＜0.05 with model group
Chinese medicine Tang blade low dose group promotes the fall generation of cell of red system and grain monokaryon assembly; Middle dose groups has promoted the proliferation and differentiation of more primary hemopoietic progenitor cell; Therefore can infer that Tang's blade promotes the recovery of hemopoietic function, can promote that with it the effect of hematopoietic stem proliferation and differentiation is relevant.Bone marrow cells in mice colony cultivation results has verified that further Tang's blade promotes the function of bone marrow hematogenesis.
6. the variation of the weight of animals
Table 7 the weight of animals changes (g)
Annotate: * and matched group ratio, P＜0.05
Behind the injection mitomycin 10 days, the weight of animals generally was lower than the normal control group, but with chemotherapy before relatively obviously do not reduce, body weight is still in increasing gradually subsequently, possible medicine to the body weight influence of animal and not quite.
7. Chinese medicine Tang blade is to the influence of mitomycin antitumor action
Chinese medicine Tang blade group, not treatment group, the tumor body expands, and there is water sample liquid the centre, and mitomycin group and combined group tumor body are little, middle no water sample liquid.Tang's blade, mitomycin effect separately are not obvious to the inhibitory action of S180 sarcoma, but unite both in animal body suppression ratio reach 43.5%.
Ascites and dead appears in animal of the independent set of applications of mitomycin after 43 days.Mitomycin and Chinese medicine Tang blade combined group animal all survive (observing 60 days), show that Chinese medicine Tang blade has the mitomycin of enhancing antitumor action.
8. Chinese medicine Tang blade is to the influence of tumor animal blood cell count
The variation (* 10 of table 8S180 sarcoma mice PBC number
9/ L)
Annotate: * and matched group ratio, P＜0.05,
▲With mitomycin group ratio, P＜0.05
The variation (* 10 of table 9S180 ascites tumor mice PBC number
9/ L)
Annotate: * and matched group ratio, P＜0.05,
▲With mitomycin group ratio, P＜0.05
In the solid tumor zoopery, leukocyte count is lower than other groups in the combination group mice peripheral blood, and is agnogenio.It might be the minimum point that the time point measured just in time is in the combination group leukocyte count.
Because the ascites tumor treated animal of not accepting the ascites tumor group of any treatment and only accepting the blade treatment of Chinese medicine Tang is in the time of the 17 day, majority is dead, does not therefore measure the PBC number.And various blood cell counts are higher than and single use the mitomycin group in combination group ascites tumor mice peripheral blood, but have only RBC number that significant difference is arranged, and other organize P＜0.1, should be also meaningful, and similar with expected result.Compare difference with the solid tumor animal and be that the ascites tumor mice gets moment in evening more behind injection mitomycin blood time, the time of using Chinese medicine Tang blade is more longer, possibly be that this group medicine has longer action time and performance time at animal body.
Six. the result
1. set up stable murine interleukin with mitomycin and reduced model.
2. dosage (1.0g/kg body weight), low dosage (0.5g/kg body weight) group can promote leukocytic rising in the model in the Chinese medicine Tang blade; Similar to neutrophilic granulocyte and lymphocytic facilitation and leukocyte, Chinese medicine Tang blade low dose group leukogenic effect is more obvious; Middle dosage Chinese medicine Tang blade also has the effect of certain leukocyte increasing.
3. Chinese medicine Tang blade can increase animal bone marrow colony forming cell number, is the embodiment of its function of increasing leukocyte.
4. Chinese medicine Tang blade accepts in the chemotherapeutics mitomycin therapeutic process effect of leukocyte increasing is arranged at tumor animal.
5. Chinese medicine Tang blade and antitumor drug share the antitumor action that can improve antineoplastic chemotherapy medicine.
6. Chinese medicine Tang blade can be alleviated the inhibitory action of antitumor drug to bone marrow.
Claims (6)
1. the application of Chinese medicine Tang blade in preparation leukocyte increasing medicine.
2. according to the application of the said Chinese medicine of claim 1 Tang blade in preparation leukocyte increasing medicine; It is characterized in that the raw material of Chinese medicine constituent of said Chinese medicine Tang blade is following weight proportion: Herba Erodii 120-150, Radix Astragali 120-150, Herba Solani Nigri 120-200, Flos Lonicerae 120-200, Flos Bombacis Malabarici 60-100, Fructus Chebulae 40-60, Herba Hedyotidis Diffusae 80-150, Pericarpium Granati 40-60, Radix Oryzae Glutinosae 150-200, Pedicellus et Pericarpium Trapae 80-150. Pericarpium Trichosanthis 40-60, Radix Bupleuri 60-100, Herba Moslae 40-60, Radix Glycyrrhizae 60-80, Caulis Spatholobi 120-150, Flos Carthami 40-60, Folium Ginkgo 40-60, Herba Portulacae 60-120, Rhizoma Picrorhizae 40-60, Scorpio 28-40.
3. according to the application of claim 1, it is characterized in that the raw material of Chinese medicine constituent of said Chinese medicine Tang blade is following weight proportion:
Herba Erodii 120-150, Radix Astragali 120-150, Herba Solani Nigri 120-200, Flos Lonicerae 120-200, Flos Bombacis Malabarici 60-100, Fructus Chebulae 40-60, Herba Hedyotidis Diffusae 80-150, Pericarpium Granati 40-60, Radix Oryzae Glutinosae 150-200, Pedicellus et Pericarpium Trapae 80-150.
4. according to the application of claim 1, it is characterized in that the raw material of Chinese medicine constituent of said Chinese medicine Tang blade is following weight proportion:
Herba Erodii 180, the Radix Astragali 180, Herba Solani Nigri 180, Flos Lonicerae 180, Flos Bombacis Malabarici 120, Fructus Chebulae 90, Herba Hedyotidis Diffusae 180, Pericarpium Granati 90, Radix Oryzae Glutinosae 300, Pedicellus et Pericarpium Trapae 180.
5. according to the application of claim 1, it is characterized in that said medicine is for increasing the medicine of animal bone marrow colony forming cell number.
6. according to the application of claim 1, it is characterized in that said medicine is for alleviating the inhibiting medicine of antitumor drug to bone marrow.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102293969A CN102335353A (en) | 2010-07-16 | 2010-07-16 | Application of traditional Chinese medicine Tangcao tablets in preparation of medicines used for increasing leukocyte |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102293969A CN102335353A (en) | 2010-07-16 | 2010-07-16 | Application of traditional Chinese medicine Tangcao tablets in preparation of medicines used for increasing leukocyte |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102335353A true CN102335353A (en) | 2012-02-01 |
Family
ID=45511453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102293969A Pending CN102335353A (en) | 2010-07-16 | 2010-07-16 | Application of traditional Chinese medicine Tangcao tablets in preparation of medicines used for increasing leukocyte |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335353A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679658A (en) * | 2004-04-09 | 2005-10-12 | 北京奇杰源医药科技发展有限公司 | Chinese medicine preparation for treating AIDS and process thereof |
-
2010
- 2010-07-16 CN CN2010102293969A patent/CN102335353A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679658A (en) * | 2004-04-09 | 2005-10-12 | 北京奇杰源医药科技发展有限公司 | Chinese medicine preparation for treating AIDS and process thereof |
Non-Patent Citations (3)
| Title |
|---|
| > 20090831 杨莉娅等 唐草片改善HIV/AIDS症状提高生活质量的实践与探讨 76-78 1-6 , * |
| 杨茂彬等: "唐草片与HAART疗法合用治疗HIV/AIDS临床研究报告", <<中华中医药学会防治艾滋病分会第六届学术年会论文汇编>> * |
| 杨莉娅等: "唐草片改善HIV/AIDS症状提高生活质量的实践与探讨", <<中国中医药现代远程教育>> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6911221B2 (en) | Anti-neoplastic drug | |
| CN1305515C (en) | Chinese medicine powder and decoction composition for treating cancers | |
| CN101120977B (en) | Medicine for treating tumor | |
| CN102631518B (en) | New medicament for treating leukemia | |
| CN102319376B (en) | Chinese herbal medicament for treating nephropathy | |
| CN100566743C (en) | A kind of Chinese herbal medicine that suppresses tumor and preparation method thereof | |
| CN102335353A (en) | Application of traditional Chinese medicine Tangcao tablets in preparation of medicines used for increasing leukocyte | |
| CN102872385A (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN1322893C (en) | Acne eliminating tablet and its prepn process | |
| CN1168457C (en) | Xiangshen injection and preparation process and use thereof | |
| CN104689088B (en) | A kind of Chinese medicine preparation and preparation method of prevention immunosenescence | |
| CN110123825B (en) | Pharmaceutical composition containing demethoxydaunorubicin | |
| CN102416087A (en) | Chinese medicinal composition for treating pelvic inflammatory disease and preparation method as well as application thereof | |
| CN103127296B (en) | Traditional Chinese medicine composition with lung cancer chemotherapeutic effect-enhancing and toxicity-reducing functions as well as preparation method and application thereof | |
| CN102872374B (en) | Chinese medicinal composition for assisting tumor radiotherapy | |
| CN110327320B (en) | A Chinese medicinal composition with leukocyte increasing effect | |
| CN104473946A (en) | Pharmaceutical composition used for treating leukemia | |
| Li et al. | Effects of traditional Chinese herbal medicines on blood parameters and antibody level in laying hens | |
| CN100443093C (en) | AIDS treating medicine | |
| CN100443092C (en) | Granulocyte raised drug comprising cepharanthine | |
| CN105030948A (en) | Drug combination and new application of preparation thereof | |
| CN103585240B (en) | One treats leukemic pharmaceutical composition and preparation method thereof | |
| CN103585221B (en) | One treats leukemic pharmaceutical composition and preparation method thereof | |
| CN102302718B (en) | Antitumor medicinal composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120201 |